TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.49 Million EUR | -52.47% |
| 2022 | 5.24 Million EUR | -46.35% |
| 2021 | 9.76 Million EUR | -8.32% |
| 2020 | 10.65 Million EUR | 515.13% |
| 2019 | 1.73 Million EUR | -61.66% |
| 2018 | 4.51 Million EUR | 386.33% |
| 2017 | 929 Thousand EUR | -67.62% |
| 2016 | 2.86 Million EUR | -52.51% |
| 2015 | 6.04 Million EUR | 95.5% |
| 2014 | 3.09 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.94 Million EUR | 0.0% |
| 2023 FY | 2.49 Million EUR | -52.47% |
| 2023 Q4 | 2.49 Million EUR | 0.0% |
| 2023 Q3 | 2.49 Million EUR | -28.05% |
| 2023 Q1 | 3.46 Million EUR | -33.94% |
| 2023 Q2 | 3.46 Million EUR | 0.0% |
| 2022 Q3 | 5.24 Million EUR | -36.72% |
| 2022 Q1 | 8.28 Million EUR | -15.21% |
| 2022 Q2 | 8.28 Million EUR | 0.0% |
| 2022 FY | 5.24 Million EUR | -46.35% |
| 2022 Q4 | 5.24 Million EUR | 0.0% |
| 2021 Q2 | 14.04 Million EUR | 0.0% |
| 2021 Q1 | 14.04 Million EUR | 31.78% |
| 2021 Q4 | 9.76 Million EUR | 0.0% |
| 2021 FY | 9.76 Million EUR | -8.32% |
| 2021 Q3 | 9.76 Million EUR | -30.43% |
| 2020 Q4 | 10.65 Million EUR | 0.0% |
| 2020 FY | 10.65 Million EUR | 515.13% |
| 2020 Q2 | 10.93 Million EUR | 0.0% |
| 2020 Q1 | 10.93 Million EUR | 531.58% |
| 2020 Q3 | 10.65 Million EUR | -2.61% |
| 2019 Q4 | 1.73 Million EUR | 0.0% |
| 2019 FY | 1.73 Million EUR | -61.66% |
| 2019 Q3 | 1.73 Million EUR | -12.66% |
| 2019 Q2 | 1.98 Million EUR | 0.0% |
| 2019 Q1 | 1.98 Million EUR | -56.11% |
| 2018 Q3 | 4.51 Million EUR | 334.42% |
| 2018 Q4 | 4.51 Million EUR | 0.0% |
| 2018 FY | 4.51 Million EUR | 386.33% |
| 2018 Q1 | 1.04 Million EUR | 11.95% |
| 2018 Q2 | 1.04 Million EUR | 0.0% |
| 2017 Q3 | 929 Thousand EUR | -38.48% |
| 2017 FY | 929 Thousand EUR | -67.62% |
| 2017 Q1 | 1.51 Million EUR | -47.37% |
| 2017 Q2 | 1.51 Million EUR | 0.0% |
| 2017 Q4 | 929 Thousand EUR | 0.0% |
| 2016 Q1 | 2.53 Million EUR | -58.09% |
| 2016 Q3 | 2.86 Million EUR | 13.31% |
| 2016 Q4 | 2.86 Million EUR | 0.0% |
| 2016 FY | 2.86 Million EUR | -52.51% |
| 2016 Q2 | 2.53 Million EUR | 0.0% |
| 2015 FY | 6.04 Million EUR | 95.5% |
| 2015 Q4 | 6.04 Million EUR | 0.0% |
| 2015 Q3 | 6.04 Million EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2014 FY | 3.09 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 83.066% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 99.238% |
| Adocia SA | 24.95 Million EUR | 90.018% |
| Aelis Farma SA | 26.28 Million EUR | 90.522% |
| Biophytis S.A. | 11.93 Million EUR | 79.13% |
| Advicenne S.A. | 12.4 Million EUR | 79.923% |
| genOway Société anonyme | 31.84 Million EUR | 92.177% |
| IntegraGen SA | 8 Million EUR | 68.864% |
| Medesis Pharma S.A. | 1.92 Million EUR | -29.313% |
| Neovacs S.A. | 47.53 Million EUR | 94.759% |
| NFL Biosciences SA | 3.97 Million EUR | 37.264% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 83.296% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | 33.516% |
| Sensorion SA | 46.49 Million EUR | 94.642% |
| Theranexus Société Anonyme | 7.23 Million EUR | 65.583% |
| Valbiotis SA | 33.24 Million EUR | 92.508% |
| TheraVet SA | 7.53 Million EUR | 66.937% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 92.938% |
| argenx SE | 4.11 Billion EUR | 99.939% |
| BioSenic S.A. | 9.55 Million EUR | 73.941% |
| Celyad Oncology SA | 16.28 Million EUR | 84.701% |
| DBV Technologies S.A. | 165.65 Million USD | 98.496% |
| Galapagos NV | 4.35 Billion EUR | 99.943% |
| Genfit S.A. | 173.87 Million EUR | 98.567% |
| GeNeuro SA | 6.31 Million EUR | 60.541% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 94.776% |
| Innate Pharma S.A. | 184.19 Million EUR | 98.648% |
| Inventiva S.A. | 69.13 Million EUR | 96.397% |
| MaaT Pharma SA | 42.93 Million EUR | 94.198% |
| MedinCell S.A. | 36.94 Million EUR | 93.258% |
| Nanobiotix S.A. | 93.89 Million EUR | 97.347% |
| Onward Medical N.V. | 43.62 Million EUR | 94.29% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 97.67% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 96.958% |
| Oxurion NV | 6.55 Million EUR | 61.969% |
| Pharming Group N.V. | 426.33 Million EUR | 99.416% |
| Poxel S.A. | 4.82 Million EUR | 48.352% |
| GenSight Biologics S.A. | 9.08 Million EUR | 72.587% |
| Transgene SA | 45.21 Million EUR | 94.491% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.87% |
| UCB SA | 15.53 Billion EUR | 99.984% |
| Valneva SE | 469.39 Million EUR | 99.469% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 91.92% |